Inovio Product Pipeline: Cancer DNA Vaccines
DNA vaccine technology has created the potential for a new generation of cancer vaccines. Inovio has a proprietary DNA vaccine candidate targeting human papillomavirus and cervical cancer. License partners and other collaborators are also using Inovio's electroporation DNA delivery technology to facilitate their vaccine research. While these DNA vaccine candidates are primarily intended to treat cancers, they may also provide preventive capabilities.
Multiple clinical studies are progressing and are described in the following sections.